ArticleFrontiers in neurology
The clinical significance of S100B, APP, and CHI3L1 in autoimmune GFAP astrocytopathy.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune glial fibrillary acidic protein astrocytopathy (A-GFAP-A) is a recently defined immune-mediated disorder of the central nervous system (CNS). At present, diagnosis relies primarily on the detection of GFAP-IgG in cerebrospinal fluid (CSF); however, the limited specificity of this biomarker restricts its clinical utility. This study aimed to investigate the expression profiles and clinical relevance of additional protein biomarkers in A-GFAP-A. Methods: A total of 19 patients with A-GFAP-A, 28 patients with neuromyelitis optica spectrum disorder (NMOSD), 12 patients with non-inflammatory neurological diseases (NINDC), and 12 healthy controls (HC) were enrolled. Serum and CSF levels of S100 calcium-binding protein B (S100B), amyloid precursor protein (APP), and chitinase-3-like protein 1 (CHI3L1) were quantitatively measured using enzyme-linked immunosorbent assay (ELISA). Disease severity was assessed using the Expanded Disability Status Scale (EDSS). Correlations between biomarker levels and clinical parameters were analyzed to evaluate their diagnostic and pathophysiological significance. Results: Serum S100B levels were significantly higher in the A-GFAP-A group than in the NMOSD group ( Conclusion: Serum S100B and APP, as well as CSF APP and CHI3L1, show potential as auxiliary diagnostic biomarkers for A-GFAP-A. These biomarkers may contribute to differential diagnosis and provide insights into disease mechanisms, thereby supporting more precise clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.